Author: Hertanto, Decsa Medika; Wiratama, Bayu Satria; Sutanto, Henry; Wungu, Citrawati Dyah Kencono
Title: Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future Cord-id: 2635es8k Document date: 2021_7_20
ID: 2635es8k
Snippet: In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccine development, COVID-19 therapy remains challenging. Several repurposed
Document: In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccine development, COVID-19 therapy remains challenging. Several repurposed drugs that were documented to be useful in small clinical trials have been shown to be ineffective in larger studies. Additionally, the pathophysiology of SARS-CoV-2 infection displayed the predominance of hyperinflammation and immune dysregulation in inducing multiorgan damage. Therefore, the potential benefits of both immune modulation and suppression in COVID-19 have been extensively discussed. Here, we reviewed the roles of immunomodulation as potential COVID-19 pharmacological modalities based on the existing data and proposed several new immunologic targets to be tested in the foreseeable future.
Search related documents:
Co phrase search for related documents- abl inhibitor imatinib and acute respiratory syndrome: 1, 2, 3
- accelerate improvement and acute respiratory distress syndrome: 1
- accelerate improvement and acute respiratory failure: 1
- accelerate improvement and acute respiratory syndrome: 1, 2, 3
- accelerate improvement and long covid: 1
- accelerate improvement and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
- action exact mechanism and acute respiratory syndrome: 1, 2, 3
- action exact mechanism unclear and acute respiratory syndrome: 1
- acute respiratory distress syndrome and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
- acute respiratory distress syndrome and low lactate: 1, 2, 3
- acute respiratory distress syndrome and low lactate dehydrogenase: 1, 2
- acute respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
- acute respiratory distress syndrome and lung alveolar cell: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory distress syndrome patient and long covid: 1, 2, 3, 4
- acute respiratory distress syndrome patient and lopinavir ritonavir: 1
- acute respiratory distress syndrome patient and low mortality: 1
- acute respiratory failure and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
Co phrase search for related documents, hyperlinks ordered by date